Lipegfilgrastim
Lonquex (lipegfilgrastim) is a protein pharmaceutical. Lipegfilgrastim was first approved as Lonquex on 2013-07-25. It has been approved in Europe to treat neutropenia.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
265 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 5 | 19 | 3 | — | — | 24 | |
| Chemotherapy-induced febrile neutropenia | D064146 | — | 4 | 7 | — | 1 | 11 | ||
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 6 | 6 | 1 | — | — | 10 | |
| Neoplasms | D009369 | C80 | 6 | 2 | 1 | — | — | 9 | |
| Sarcoma | D012509 | 1 | 5 | 1 | — | 2 | 8 | ||
| Multiple myeloma | D009101 | C90.0 | 2 | 4 | 1 | — | — | 6 | |
| Hodgkin disease | D006689 | C81 | 4 | 4 | 1 | — | — | 6 | |
| Triple negative breast neoplasms | D064726 | 1 | 4 | 1 | — | — | 5 | ||
| Colorectal neoplasms | D015179 | 1 | 2 | 1 | — | — | 4 | ||
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 3 | 1 | — | — | 3 |
Show 11 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | C95 | 2 | 8 | — | — | — | 8 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | 6 | — | — | — | 6 | |
| Prostatic neoplasms | D011471 | C61 | 3 | 4 | — | — | — | 5 | |
| Central nervous system neoplasms | D016543 | 2 | 4 | — | — | — | 5 | ||
| Follicular lymphoma | D008224 | C82 | 3 | 2 | — | — | — | 4 | |
| Urinary bladder neoplasms | D001749 | C67 | — | 4 | — | — | — | 4 | |
| Mantle-cell lymphoma | D020522 | C83.1 | 2 | 2 | — | — | — | 3 | |
| Renal cell carcinoma | D002292 | 1 | 2 | — | — | — | 3 | ||
| Male breast neoplasms | D018567 | 1 | 3 | — | — | — | 3 | ||
| Teratoma | D013724 | D28 | — | 3 | — | — | — | 3 |
Show 40 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 14 | — | — | — | 1 | 15 | ||
| Therapeutic equivalency | D013810 | 3 | — | — | — | — | 3 | ||
| Neuroblastoma | D009447 | EFO_0000621 | 2 | — | — | — | — | 2 | |
| Pharmacokinetics | D010599 | 2 | — | — | — | — | 2 | ||
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| T-cell lymphoma cutaneous | D016410 | C84.A | 1 | — | — | — | — | 1 | |
| Small cell lung carcinoma | D055752 | 1 | — | — | — | — | 1 | ||
| Aids-related lymphoma | D016483 | EFO_1001365 | 1 | — | — | — | — | 1 | |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | — | — | — | — | 1 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | — | — | — | — | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LIPEGFILGRASTIM |
| INN | lipegfilgrastim |
| Description | Lipegfilgrastim, sold under the brand name Lonquex, is a medication used to reduce the duration of neutropenia and the incidence of febrile neutropenia in adults. It is given by injection under the skin in the abdomen, upper arm or thigh.
|
| Classification | Protein |
| Drug class | colony-stimulating factors: granulocyte colony-stimulating factors (G-CSF); PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1117844-87-7 |
| RxCUI | 1440046 |
| ChEMBL ID | CHEMBL4594230 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB13200 |
| UNII ID | 4AWF0N6QV3 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 120 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
45,615 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more